Paola Cavalcante

List of Publications by Year
in descending order

42 papers	1,647 citations	279798 23 h-index	315739 38 g-index
42 all docs	42 docs citations	42 times ranked	2310 citing authors

#	Article	IF	Citations
1	Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy. Biomedicines, 2022, 10, 1360.	3.2	1
2	Postinfectious Neurologic Complications in COVID-19: AÂComplex Case Report. Journal of Nuclear Medicine, 2021, 62, 1171-1176.	5.0	12
3	Dysregulation of Muscle-Specific MicroRNAs as Common Pathogenic Feature Associated with Muscle Atrophy in ALS, SMA and SBMA: Evidence from Animal Models and Human Patients. International Journal of Molecular Sciences, 2021, 22, 5673.	4.1	14
4	Next-Generation Sequencing Identifies Extended HLA Class I and II Haplotypes Associated With Early-Onset and Late-Onset Myasthenia Gravis in Italian, Norwegian, and Swedish Populations. Frontiers in Immunology, 2021, 12, 667336.	4.8	3
5	COVIDâ€19â€associated immuneâ€mediated encephalitis mimicking acuteâ€onset Creutzfeldtâ€Jakob disease. Annals of Clinical and Translational Neurology, 2021, 8, 2314.	3.7	5
6	Pharmacogenetic and pharmaco-miR biomarkers for tailoring and monitoring myasthenia gravis treatments. Expert Review of Precision Medicine and Drug Development, 2020, 5, 317-329.	0.7	2
7	miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids. Frontiers in Immunology, 2020, 11, 142.	4.8	26
8	Cytokine Profile in Striated Muscle Laminopathies: New Promising Biomarkers for Disease Prediction. Cells, 2020, 9, 1532.	4.1	8
9	Eculizumab for the treatment of myasthenia gravis. Expert Opinion on Biological Therapy, 2020, 20, 991-998.	3.1	10
10	Complement Inhibition for the Treatment of Myasthenia Gravis . ImmunoTargets and Therapy, 2020, Volume 9, 317-331.	5.8	27
11	Hyperexcitability in Cultured Cortical Neuron Networks from the G93A-SOD1 Amyotrophic Lateral Sclerosis Model Mouse and its Molecular Correlates. Neuroscience, 2019, 416, 88-99.	2.3	14
12	MicroRNA signature associated with treatment response in myasthenia gravis: A further step towards precision medicine. Pharmacological Research, 2019, 148, 104388.	7.1	16
13	FM19G11-Loaded Gold Nanoparticles Enhance the Proliferation and Self-Renewal of Ependymal Stem Progenitor Cells Derived from ALS Mice. Cells, 2019, 8, 279.	4.1	26
14	Diagnosis and treatment of myasthenia gravis. Current Opinion in Rheumatology, 2019, 31, 623-633.	4.3	40
15	Tollâ€like receptors 7 and 9 in myasthenia gravis thymus: amplifiers of autoimmunity?. Annals of the New York Academy of Sciences, 2018, 1413, 11-24.	3.8	28
16	Elevated TGF Î²2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes. Nucleus, 2018, 9, 337-349.	2.2	25
17	Myasthenia gravis: from autoantibodies to therapy. Current Opinion in Neurology, 2018, 31, 517-525.	3.6	58
18	Revealing the involvement of miR-376a, miR-432 and miR-451a in infantile ascending hereditary spastic paralysis by microRNA profiling in iPSCs. Journal of Translational Science, 2018, 5, .	0.2	0

#	Article	IF	Citations
19	Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?. Oncotarget, 2017, 8, 95432-95449.	1.8	23
20	A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients. Immunobiology, 2016, 221, 1227-1236.	1.9	33
21	Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epsteinâ€"Barr virus infection. Immunobiology, 2016, 221, 516-527.	1.9	47
22	Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins. Oncotarget, 2015, 6, 7424-7437.	1.8	25
23	Up-regulation of neural and cell cycle-related microRNAs in brain of amyotrophic lateral sclerosis mice at late disease stage. Molecular Brain, 2015, 8, 5.	2.6	49
24	<scp>VAV</scp>1 and <scp>BAFF</scp>, via <scp>NF</scp>Îº B pathway, are genetic risk factors for myasthenia gravis. Annals of Clinical and Translational Neurology, 2014, 1, 329-339.	3.7	27
25	Altered miRNA expression is associated with neuronal fate in G93A-SOD1 ependymal stem progenitor cells. Experimental Neurology, 2014, 253, 91-101.	4.1	31
26	Innate immunity in myasthenia gravis thymus: Pathogenic effects of Toll-like receptor 4 signaling on autoimmunity. Journal of Autoimmunity, 2014, 52, 74-89.	6.5	62
27	Etiology of myasthenia gravis: Innate immunity signature in pathological thymus. Autoimmunity Reviews, 2013, 12, 863-874.	5.8	75
28	A New Thiopurine Sâ€Methyltransferase Haplotype Associated With Intolerance to Azathioprine. Journal of Clinical Pharmacology, 2013, 53, 67-74.	2.0	21
29	Autoimmune mechanisms in myasthenia gravis. Current Opinion in Neurology, 2012, 25, 621-629.	3.6	62
30	Hind limb muscle atrophy precedes cerebral neuronal degeneration in G93A-SOD1 mouse model of amyotrophic lateral sclerosis: A longitudinal MRI study. Experimental Neurology, 2011, 231, 30-37.	4.1	81
31	The thymus in myasthenia gravis: Site of â€œinnate autoimmunityâ€?. Muscle and Nerve, 2011, 44, 467-484.	2.2	56
32	Epsteinâ€barr virus in myasthenia gravis thymus: A matter of debate. Annals of Neurology, 2011, 70, 519-519.	5.3	9
33	Inflammation and Epstein-Barr Virus Infection Are Common Features of Myasthenia Gravis Thymus: Possible Roles in Pathogenesis. Autoimmune Diseases, 2011, 2011, 1-17.	0.6	25
34	Epsteinâ€Barr virus persistence and reactivation in myasthenia gravis thymus. Annals of Neurology, 2010, 67, 726-738.	5.3	103
35	Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis. Neurology, 2010, 74, 1118-1126.	1.1	51
36	BDNF and its receptors in human myasthenic thymus: Implications for cell fate in thymic pathology. Journal of Neuroimmunology, 2008, 197, 128-139.	2.3	14

#	Article	IF	Citations
37	Thymoma-associated myasthenia gravis: Outcome, clinical and pathological correlations in 197 patients on a 20-year experience. Journal of Neuroimmunology, 2008, 201-202, 237-244.	2.3	73
38	Characterization of a bidirectional promoter shared between two human genes related to aging: SIRT3 and PSMD13. Genomics, 2007, 89, 143-150.	2.9	78
39	Gene expression of cytokines and cytokine receptors is modulated by the common variability of the mitochondrial DNA in cybrid cell lines. Genes To Cells, 2006, 11, 883-891.	1.2	47
40	A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. Genomics, 2005, 85, 258-263.	2.9	339
41	Paraneoplastic autoimmune diseases in patients with thymic malignancies: a favorable, but not independent, prognostic factor. Mediastinum, 0, 2, 41-41.	1.1	1
42	Epstein-Barr Virus in Myasthenia Gravis: Key Contributing Factor Linking Innate Immunity with B-Cell-Mediated Autoimmunity. , 0, , .		0